CagriSema Approval: Current Status, Timeline, and What to Expect

CagriSema is not approved by the FDA for weight loss, type 2 diabetes, or any other use in the United States. Novo Nordisk has completed its Phase 3 REDEFINE trials and has said it intends to file the drug for regulatory review, but no agency decision has been issued and no PDUFA date has been announced. Any exact CagriSema approval date you see online today is a projection, not a confirmed fact.

Is CagriSema Approved in Any Market Yet?

No. CagriSema has not received marketing authorization in the United States, the European Union, the United Kingdom, Canada, or South Africa. German-language searches for "Novo Nordisk CagriSema Zulassung" are asking the same question US patients are asking: when will regulators clear it?

Two milestones are easy to mix up. A trial readout shows how a drug performed in a study, while an approval is a regulator's formal decision that the benefits outweigh the risks for a specific use. Strong trial data is a step toward approval, but it is not the same thing.

Market	Regulator	Status
United States	FDA	Not approved; no PDUFA date announced
European Union	EMA	Not approved; no marketing authorization
United Kingdom	MHRA	Not approved
Canada	Health Canada	Not approved
South Africa	SAHPRA	Not approved

What Is CagriSema and How Does It Work?

CagriSema is a once-weekly injectable that combines cagrilintide, a long-acting amylin analog, with semaglutide, the GLP-1 receptor agonist sold as Ozempic and Wegovy. The two molecules act on different appetite and satiety pathways, which is why researchers expect the combination to outperform either component alone.

The Phase 3 program is called REDEFINE. It includes REDEFINE 1 in adults with obesity or overweight plus a weight-related condition, REDEFINE 2 in adults with type 2 diabetes and excess weight, and REDEFINE 3, an ongoing cardiovascular outcomes trial. One exploratory arm also tested a fixed-dose combination known as CagriSema Sema 2.4.

CagriSema Approval Timeline, Filings, and PDUFA Dates

Approval does not start with a press release. It starts when a company submits a New Drug Application or similar filing, and the FDA has 60 days to decide whether to accept it for review. Only after acceptance does the agency set a PDUFA date, which is the target deadline for its decision.

Standard FDA reviews run about 10 months from the filing date, while priority reviews run about six. Novo Nordisk has indicated it intends to file CagriSema for approval in 2025, and company guidance has pointed to a possible launch in 2026 if the review goes smoothly. That guidance is not a guarantee, and review timelines can slip.

For a sense of how unpredictable these timelines can be, many analysts compare CagriSema's path with other regulatory milestones, such as ss 31 fda approval, to illustrate how widely review times vary from one product to the next.

What Did the REDEFINE Trials Show?

Novo Nordisk has released topline results from the first two REDEFINE trials. The headline numbers are what drive the current optimism about CagriSema.

• In REDEFINE 1, participants without diabetes lost an average of about 22.7% of their body weight at 68 weeks when they stayed on treatment, with roughly 20% average loss in the primary analysis that counted everyone who enrolled.
• In REDEFINE 2, adults with type 2 diabetes and overweight or obesity lost substantially more weight on CagriSema than on placebo, with average reductions in the mid-teens percentage range at 68 weeks.
• Gastrointestinal side effects such as nausea, vomiting, and constipation were the most common complaints, and a minority of participants stopped treatment because of them.

These results are encouraging but incomplete. REDEFINE 3 is still running, and regulators will review the full dataset, including detailed safety data, before making any decision.

How CagriSema Compares With Approved Weight Loss Drugs

If CagriSema is approved, it would enter a market currently led by two drugs. Direct comparisons across trials should be read with caution because study populations, doses, and designs differ.

Drug	Status	Mechanism	Average weight loss in pivotal trial
Wegovy (semaglutide 2.4 mg)	FDA-approved for obesity	GLP-1 receptor agonist	About 15% at 68 weeks
Zepbound (tirzepatide)	FDA-approved for obesity	GIP and GLP-1 dual agonist	About 21% at 72 weeks
CagriSema	Investigational; not approved	Amylin analog plus GLP-1 agonist	About 20-23% at 68 weeks (REDEFINE 1)

Wegovy and Zepbound are the approved options most often compared with CagriSema. CagriSema is not FDA-approved, so it cannot be prescribed or dispensed in the United States today.

Pricing, Access, and What to Watch Next

Following reliable cagrisema news sources and Novo Nordisk's own investor updates is more useful than social media rumors when tracking filing status. Novo Nordisk has not published a US list price for the product.

Once approved, cagrisema price will depend on the list price, insurance coverage, and whether pharmacy benefit managers place it on formularies. People searching for cagrisema where to buy today are usually encountering gray-market sellers, and products sold that way are not verified for safety, purity, or dose.

Dosing is unsettled as well. A cagrisema dosage chart circulating on the internet is not an approved prescribing schedule, and the final label will only exist after regulators complete their review.

Safety and What Patients Can Do Now

GLP-1-based medicines commonly cause nausea, vomiting, diarrhea, and constipation, especially during dose increases. Less common but serious risks include pancreatitis, gallbladder disease, and gastroparesis, and rapid weight loss can also mean losing lean muscle mass.

Because CagriSema is investigational, it cannot legally be prescribed in the United States, and buying it from unverified sources is risky. Anyone who wants to lose weight now should talk with a healthcare professional about approved options such as semaglutide and tirzepatide, and about realistic expectations for side effects and cost.

This article is general information only and is not medical advice.

COMMON QUESTIONS

Frequently Asked Questions

Is CagriSema approved by the FDA?

No. The FDA has not approved CagriSema for weight loss, type 2 diabetes, or any other indication. Novo Nordisk has said it plans to submit the drug for review, but no filing has been accepted and no PDUFA date has been announced. Until the FDA issues an approval, CagriSema cannot legally be prescribed in the United States.

When will CagriSema be available?

There is no confirmed release date. Novo Nordisk guidance has pointed to a possible launch in 2026 if regulators accept and review the application on a standard timeline. FDA decisions typically come about 10 months after a filing is accepted, and delays are common in drug review.

Will CagriSema be available in South Africa?

CagriSema is not approved in South Africa, and no review timeline has been publicly confirmed with SAHPRA. Novo Nordisk has prioritized the US and European filings, so availability in South Africa would likely follow those markets. Patients in South Africa should ask a healthcare professional about currently approved weight management options.